BMA
Banco Macro S.A.
There isn't enough reported data to score BMA yet.
JPM
JPMorgan Chase & Co.
JPM's fundamentals are strong, but it looks expensive: trading at 14x earnings, above its usual 12x. Analysts expect earnings growth.
BMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| N/A | |
| N/A |
BMA's profitability is currently stable. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like BMA.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
BMA PE Valuation
BMA has no meaningful PE right now: it lost money over the past year.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
BMA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for BMA, with profitability improving.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
BMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | $2.98 | -59% |
| Q2 2025 | $4.23 | -35% |
| Q1 2025 | -$0.48 | -104% |
| Q4 2024 | $3.45 | -51% |
| Q3 2024 | $7.21 | +226% |
| Q2 2024 | $6.52 | +198% |
| Q1 2024 | $11.38 | +1735% |
| Q4 2023 | $7.10 | +1009% |
JPM has the stronger earnings trend. Trailing diluted EPS is down 59% for BMA versus JPM up 18%.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM's earnings per share have climbed steadily: $23.85 over the past year, up 18% from the year before, and higher year over year for 15 quarters in a row.
BMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $950.1M | +4.1% |
| Q1 2026 | $1.2B | +70% |
| Q3 2025 | $933.9M | +30% |
| Q2 2025 | $912.7M | +16% |
| Q1 2025 | $725M | -66% |
| Q4 2024 | $970.7M | -44% |
| Q3 2024 | $719.9M | -46% |
| Q2 2024 | $789.5M | -29% |
BMA has the stronger quarterly revenue trend. Revenue is up 31% for BMA versus up 8.1% for JPM.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 22% | +15 points |
| Q1 2026 | 11% | -0.1 points |
| Q3 2025 | -2.6% | -14 points |
| Q2 2025 | 17% | +59 points |
| Q1 2025 | 7.2% | -10 points |
| Q4 2024 | 11% | -17 points |
| Q3 2024 | 11% | +8 points |
| Q2 2024 | -41% | -55 points |
BMA's operating margin was 22% last quarter, up 15 points from the same quarter a year ago, near the top of its range since 2019.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over BMA on profitability, with a higher operating margin.
BMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $372.3M | +$984.4M |
| Q1 2026 | $384.5M | +$1B |
| Q3 2025 | $304.5M | -63% |
| Q2 2025 | -$612.1M | -271% |
| Q1 2025 | -$616.8M | -10886964% |
| Q4 2024 | -$353.2M | -$232.5M |
| Q3 2024 | $818.8M | +$896.2M |
| Q2 2024 | $357M | +$365.4M |
BMA has the stronger cash trend. Its trailing FCF is up 207% versus its history, compared with JPM at down 229%.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
BMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -38K shares |
| 1 year | -0.1% | -40.3K shares |
| 3 years | -0.1% | -40.3K shares |
| 5 years | -1.2% | -804K shares |
| Available history | -0.1% | -38.8K shares |
BMA has 64M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over BMA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
BMA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -3.1x | Net Cash |
| Q2 2025 | -2.0x | Net Cash |
| Q1 2025 | -57.5x | Net Cash |
| Q4 2024 | -4.4x | Net Cash |
| Q3 2024 | -2.8x | Net Cash |
| Q2 2024 | -1.3x | Net Cash |
| Q1 2024 | -0.4x | Net Cash |
| Q4 2023 | -1.5x | Net Cash |
BMA has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BMA.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
BMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.6 | Neutral |
| Stochastic | 4.0 | Oversold |
BMA's weekly RSI is 33 (neutral) and its Stochastic is 4 (oversold).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
BMA PE vs Financial Services Sector
BMA has no meaningful PE right now: it lost money over the past year.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
BMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.7 | 12% below |
| 20 week MA | $75.0 | 26% below |
| 50 week MA | $80.5 | 31% below |
| 100 week MA | $79.3 | 30% below |
| 200 week MA | $59.4 | 6.9% below |
BMA is in a downtrend: it's below all five of its weekly moving averages, and 6.9% below its 200-week average.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over BMA on trend strength, trading above more of its moving averages.
BMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.4 | $15.6 | -57% |
| 2021 | $15.6 | $14.6 | -6.6% |
| 2022 | $14.6 | $15.8 | +8.9% |
| 2023 | $15.8 | $28.7 | +81% |
| 2024 | $28.7 | $100.2 | +249% |
| 2025 | $100.2 | $91.4 | -8.8% |
| 2026 YTD | $91.4 | $55.2 | -40% |
BMA's yearly returns have swung widely, from +249% in 2024 to −57% in 2020. It's down 40% so far in 2026.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over BMA on returns for 2026, with the stronger performance.